Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Nerlynx (neratinib)
pCPA File Number:
21178
Negotiation Status:
Negotiations were not pursued
Indication(s):
Hormone Receptor-Positive Breast Cancer
Sponsor/Manufacturer:
Knight Therapeutics
CADTH Project Number:
10172
pCPA Engagement Letter Issued:
2020-02-04
Negotiation Process Concluded:
2020-02-04